CryoPort (CYRX)


Market Price (11/19/2026): $20.17 | Market Cap: $1.0 BilSector: Industrials | Industry: Air Freight & Logistics

CryoPort (CYRX)


Market Price (11/19/2026): $20.17
Market Cap: $1.0 Bil
Sector: Industrials
Industry: Air Freight & Logistics

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%

Megatrend and thematic drivers
Megatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support.

Trading close to highs
Dist 52W High is -2.7%, Dist 3Y High is -2.7%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -38 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -20%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 93x

Stock price has recently run up significantly
12M Rtn12 month market price return is 140%

Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -10%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.1%

Key risks
CYRX key risks include [1] severe financial underperformance, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%
1 Megatrend and thematic drivers
Megatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support.
2 Trading close to highs
Dist 52W High is -2.7%, Dist 3Y High is -2.7%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -38 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -20%
4 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 93x
5 Stock price has recently run up significantly
12M Rtn12 month market price return is 140%
6 Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -10%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.1%
8 Key risks
CYRX key risks include [1] severe financial underperformance, Show more.

CYRX in ETFs

Weight = CYRX's share of each fund

VTI0.00%
ITOT0.00%
IWM0.03%
IWN0.07%
VTWO0.03%
SCHA0.02%
DFAS0.02%
VHT0.01%
+3 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 9: up 7.2% in one day (S&P 500 up 2.4%)
The stock rose without company headlines as the broader market experienced a broad-based relief rally, with the S&P 500 also advancing significantly.

Up 168.7% from its Mar 12 low to Nov 10 (S&P 500 up 13.5%)
The stock advanced over this period, primarily driven by reports of strong revenue growth, particularly in commercial cell and gene therapy, and an expansion in clinical trials. Significant gains followed Q1 2026 results on May 5, 2026, and Q3 2026 results on November 6, 2026.

Nov 6: up 19.0% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock rose following its third quarter 2026 financial results, which reported revenue growth of 14% year-over-year to $50.2 million. Commercial Cell and Gene Therapy revenue increased 20%, despite a reported loss per share.

Show more
Prices as of 11/18/2026

Nov 9: up 7.2% in one day (S&P 500 up 2.4%)
The stock rose without company headlines as the broader market experienced a broad-based relief rally, with the S&P 500 also advancing significantly.

Up 168.7% from its Mar 12 low to Nov 10 (S&P 500 up 13.5%)
The stock advanced over this period, primarily driven by reports of strong revenue growth, particularly in commercial cell and gene therapy, and an expansion in clinical trials. Significant gains followed Q1 2026 results on May 5, 2026, and Q3 2026 results on November 6, 2026.

Nov 6: up 19.0% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock rose following its third quarter 2026 financial results, which reported revenue growth of 14% year-over-year to $50.2 million. Commercial Cell and Gene Therapy revenue increased 20%, despite a reported loss per share.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 33.7% change in CYRX stock from 7/31/2026 to 11/18/2026 was primarily driven by a 29.0% change in the company's P/S Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)15.0920.1733.7%
Change Contribution By: 
Total Revenues ($ Mil)1831925.2%
P/S Multiple4.15.329.0%
Shares Outstanding (Mil)5051-1.5%
Cumulative Contribution33.7%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
CYRX33.7% 
Market (SPY)-2.0%41.4%
Sector (XLI)-8.2%27.8%

Fundamental Drivers

The 96.6% change in CYRX stock from 4/30/2026 to 11/18/2026 was primarily driven by a 82.5% change in the company's P/S Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)10.2620.1796.6%
Change Contribution By: 
Total Revenues ($ Mil)1761929.2%
P/S Multiple2.95.382.5%
Shares Outstanding (Mil)5051-1.4%
Cumulative Contribution96.6%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
CYRX96.6% 
Market (SPY)2.1%39.0%
Sector (XLI)-5.2%21.0%

Fundamental Drivers

The 118.3% change in CYRX stock from 10/31/2025 to 11/18/2026 was primarily driven by a 90.1% change in the company's P/S Multiple.
(LTM values as of)1031202511182026Change
Stock Price ($)9.2420.17118.3%
Change Contribution By: 
Total Revenues ($ Mil)16619215.7%
P/S Multiple2.85.390.1%
Shares Outstanding (Mil)5051-0.8%
Cumulative Contribution118.3%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
CYRX118.3% 
Market (SPY)8.2%42.4%
Sector (XLI)7.4%24.8%

Fundamental Drivers

The 107.9% change in CYRX stock from 10/31/2023 to 11/18/2026 was primarily driven by a 170.4% change in the company's P/S Multiple.
(LTM values as of)1031202311182026Change
Stock Price ($)9.7020.17107.9%
Change Contribution By: 
Total Revenues ($ Mil)241192-20.0%
P/S Multiple2.05.3170.4%
Shares Outstanding (Mil)4951-3.8%
Cumulative Contribution107.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
CYRX107.9% 
Market (SPY)81.1%32.3%
Sector (XLI)74.6%29.7%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
CYRX Return35%-71%-11%-50%23%110%-54%
Peers Return26%-36%11%6%-2%34%24%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
CYRX Win Rate50%42%33%50%50%55% 
Peers Win Rate57%38%52%45%52%63% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
CYRX Max Drawdown-41%-73%-65%-71%-47%-31% 
Peers Max Drawdown-29%-51%-39%-29%-37%-36% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: AZTA, BLFS, TMO, RGEN, FDX. See CYRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventCYRXS&P 500
2025 US Tariff Shock
  % Loss-31.8%-18.8%
  % Gain to Breakeven46.6%23.1%
  Time to Breakeven2 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-42.6%-9.5%
  % Gain to Breakeven74.3%10.5%
  Time to Breakeven47 days24 days
2020 COVID-19 Crash
  % Loss-27.8%-33.7%
  % Gain to Breakeven38.5%50.9%
  Time to Breakeven43 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-34.9%-19.2%
  % Gain to Breakeven53.6%23.8%
  Time to Breakeven65 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-62.9%-12.2%
  % Gain to Breakeven169.2%13.9%
  Time to Breakeven72 days62 days
2014-2016 Oil Price Collapse
  % Loss-52.6%-6.8%
  % Gain to Breakeven111.1%7.3%
  Time to Breakeven64 days15 days

Compare to AZTA, BLFS, TMO, RGEN, FDX

In The Past

CryoPort's stock fell -31.8% during the 2025 US Tariff Shock. Such a loss loss requires a 46.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventCYRXS&P 500
2025 US Tariff Shock
  % Loss-31.8%-18.8%
  % Gain to Breakeven46.6%23.1%
  Time to Breakeven2 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-42.6%-9.5%
  % Gain to Breakeven74.3%10.5%
  Time to Breakeven47 days24 days
2020 COVID-19 Crash
  % Loss-27.8%-33.7%
  % Gain to Breakeven38.5%50.9%
  Time to Breakeven43 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-34.9%-19.2%
  % Gain to Breakeven53.6%23.8%
  Time to Breakeven65 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-62.9%-12.2%
  % Gain to Breakeven169.2%13.9%
  Time to Breakeven72 days62 days
2014-2016 Oil Price Collapse
  % Loss-52.6%-6.8%
  % Gain to Breakeven111.1%7.3%
  Time to Breakeven64 days15 days
2013 Taper Tantrum
  % Loss-63.5%-0.2%
  % Gain to Breakeven174.3%0.2%
  Time to Breakeven134 days1 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-33.8%-17.9%
  % Gain to Breakeven51.0%21.8%
  Time to Breakeven1376 days123 days
2010 Eurozone Sovereign Debt Crisis / Flash Crash
  % Loss-51.1%-15.4%
  % Gain to Breakeven104.4%18.2%
  Time to Breakeven1829 days125 days
2008-2009 Global Financial Crisis
  % Loss-73.6%-53.4%
  % Gain to Breakeven278.8%114.4%
  Time to Breakeven371 days1085 days

Compare to AZTA, BLFS, TMO, RGEN, FDX

In The Past

CryoPort's stock fell -31.8% during the 2025 US Tariff Shock. Such a loss loss requires a 46.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About CryoPort (CYRX)

CryoPort (CYRX) is a life sciences services company specializing in temperature-controlled logistics solutions. It primarily focuses on ensuring the safe and stable transportation and storage of sensitive biologic commodities, such as cells, tissues, and vaccines, across global markets. Essentially, CryoPort provides critical infrastructure and services for the handling of valuable biological materials, crucial for research, clinical trials, and commercial applications in the life sciences industry.

The company's offerings include its proprietary cloud-based logistics management platform, Cryoportal, which facilitates end-to-end shipment management from order to delivery, including real-time tracking and regulatory compliance. Complementing this are their specialized CryoPort Express Shippers, designed to maintain the integrity of biologics during transit, and the SmartPak Condition Monitoring System for data collection and validation. CryoPort also supplies vacuum insulated dewars and cryogenic freezers, alongside comprehensive services like biological specimen cryopreservation storage, archiving, monitoring, and transportation.

CryoPort serves a vital role for customers in high-stakes industries where the integrity of biological materials is paramount. Its primary markets include the biopharma and pharmaceutical sectors, supporting drug development and distribution; the animal health industry; and human reproductive medicine, ensuring the safe handling of genetic materials.

AI Analysis | Feedback

Here are 1-3 brief analogies for CryoPort (CYRX):

  • Like a highly specialized FedEx or UPS, but exclusively for critical, temperature-sensitive biological materials.
  • An Iron Mountain for frozen biological samples, coupled with a global, specialized delivery network.

AI Analysis | Feedback

  • Cryoportal Platform: A cloud-based logistics management platform for order entry, documentation, real-time shipment tracking, and regulatory compliance.
  • Temperature-Controlled Shipping Solutions: Specialized shipping containers like CryoPort Express Shippers, vacuum insulated dewars, and cryogenic freezer systems to maintain biologic stability during transport.
  • Biospecimen Storage & Management: Services for the cryopreservation, archiving, monitoring, and transportation of biological specimens.
  • Logistics & Engineering Consulting: Short-term consulting engagements providing logistics support and engineering expertise.

AI Analysis | Feedback

CryoPort (CYRX) primarily sells its services and solutions to other companies within specific life sciences markets.

Based on the provided background, the company serves customers in the following categories:

  • Biopharma/Pharma Market
  • Animal Health Market
  • Human Reproductive Medicine Market

The background information does not provide the names of specific customer companies.

AI Analysis | Feedback

null

AI Analysis | Feedback

Jerrell W. Shelton President and Chief Executive Officer, Cryoport, Inc.

Jerrell Shelton has over 40 years of executive and corporate governance experience across various industries including information services, software, telecommunications, manufacturing, natural resources, and distribution. He joined Cryoport's board in October 2012 and was appointed President and CEO in November 2012, becoming Chairman in October 2015. Previously, he was a visiting executive at IBM Research, where his team developed WebFountain. He also served as President and CEO of NDC Holdings, Continental Graphics Holdings, Thomson Business Information Group, and Advantage Companies, under his leadership each of those companies achieved rapid revenue growth, improved profitability, and increased shareholder value.

Robert S. Stefanovich Chief Financial Officer and Treasurer, Cryoport, Inc.

Robert Stefanovich has over 30 years of experience in financial management and strategy, with more than 20 years as CFO in the specialty pharma, medical device, and software industries. He previously served as CFO of Novalar Pharmaceuticals, a venture-backed specialty pharmaceutical company. He also held CFO positions at three publicly traded companies: Xcorporeal, Artemis International Solutions Corporation, and Aethlon Medical. Earlier in his career, he was Vice President of Administration at SAIC, a Fortune 500 company, and an audit manager with Price Waterhouse LLP’s technology practice.

Mark W. Sawicki, Ph. D. Chief Scientific Officer, Cryoport, Inc.

Mark Sawicki brings over 20 years of executive and sales management experience, consistently achieving corporate revenue and market share goals in the pharmaceutical and biotechnology industries. He most recently served as the chief business officer at Alcami. Prior to that, he held senior business development roles at AGC Biologics and Curia, where he significantly increased revenue.

Tony Ippolito Vice President, General Counsel and Corporate Secretary, Cryoport, Inc.

Tony Ippolito has over 18 years of experience in mergers and acquisitions, securities law, and general corporate law. Before joining Cryoport, he was a partner in the Corporate and Securities practice group at Snell & Wilmer, LLP, where his practice focused on advising reporting companies in securities law matters, mergers and acquisitions, private placements, and venture capital financings. He is also a former CPA and was a forensic accountant at FTI Consulting, Inc.

Phil Wilson Senior Vice President & Chief Operating Officer, Cryoport Systems

Phil Wilson is an accomplished supply chain executive with over 25 years of industry experience. Before joining Cryoport, he served as Vice President, Supply Chain for Ancillare LP. Prior to that, he was the Director of Global Operational Programs at Catalent Pharma Solutions, where he managed various aspects of the pharmaceutical supply chain.

AI Analysis | Feedback

The key risks to Cryoport's business (CYRX) are:

  1. Dependence on successful commercialization of cell and gene therapies: Cryoport's revenue growth is heavily reliant on the successful progression of its clients' cell and gene therapies through clinical trials and subsequent commercialization, including Biologics License Application (BLA) and Marketing Authorisation Application (MAA) approvals. Any slowdown in clinical trial activity, delays in regulatory approvals, or lower-than-anticipated commercial adoption of these advanced therapies could significantly impact Cryoport's growth trajectory. The company currently holds a substantial market share in the logistics for cell and gene therapy clinical trials, making its performance closely tied to the success rates within this niche but high-growth sector.
  2. Intense competition from larger logistics providers: While Cryoport has established a strong position in the specialized and complex logistics for cell and gene therapies, it faces increasing competition, particularly as the industry evolves towards larger-scale commercial distribution, such as for allogeneic therapies. This shift brings Cryoport into direct competition with global logistics giants like DHL, UPS, and FedEx, which possess extensive global networks, greater economies of scale, and the ability to offer competitive pricing or bundled services. Cryoport's more limited presence in the high-volume commercial distribution of mainstream pharmaceuticals, a segment dominated by these larger players, also highlights a competitive weakness.
  3. Ongoing unprofitability and high financial leverage: Cryoport has consistently reported ongoing losses and negative operating margins, indicating persistent challenges in achieving profitability. While the company has shown improvements in gross margins and narrowed adjusted EBITDA losses, it is not forecasted to become profitable within the next three years. Furthermore, Cryoport carries significant financial leverage, with its net debt/EBITDA ratio notably higher than the market average, and faces a convertible debt maturity in December 2026 which will require refinancing or repayment, potentially straining its cash reserves. The company's Altman Z-Score also suggests a potential risk of financial distress.

AI Analysis | Feedback

null

AI Analysis | Feedback

CryoPort (NASDAQ: CYRX) operates within several addressable markets related to temperature-controlled logistics and cryopreservation for the life sciences industry.

  • Life Science Logistics Market (Global): The global life science logistics market was calculated at approximately USD 127.7 billion in 2024 and is projected to reach around USD 262.51 billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 7.46% between 2025 and 2034. Another estimate values the global life science logistics market at USD 123.75 billion in 2024, with a projection to grow to USD 289.35 billion by 2035 at a CAGR of 8.03% during the forecast period of 2025–2035. A different source indicates the global life science logistics market size at USD 17.69 billion in 2024, predicted to increase to approximately USD 38.19 billion by 2034, growing at a CAGR of 8.00% from 2025 to 2034.

  • Pharmaceutical Cold Chain Logistics Market (Global): This market was valued at approximately USD 27.9 billion in 2024 and is forecast to reach nearly USD 49.6 billion by 2032, with a CAGR of about 8.5%.

  • Cell and Gene Therapy Cold-Chain Logistics Market (Global): This specialized sector is estimated at USD 1.9 billion in 2024 and is projected to exceed USD 8 billion by 2034, demonstrating a CAGR of about 15.6%. The cell and gene therapy logistics sector is also projected to reach USD 37.8 billion by 2027. The commercial cell and gene therapy (CGT) market is expected to grow from USD 10 billion in 2025 to USD 38 billion by 2030, at a CAGR of approximately 30%. In North America, this market represents roughly 44% of the global total.

  • Cell Cryopreservation Market (Global): The global cell cryopreservation market size is estimated at USD 3.30 billion in 2025 and is projected to reach USD 8.68 billion by 2034, growing at a CAGR of 11.37%. Another report estimates the global cell cryopreservation market size at USD 3.38 billion in 2024, projected to reach USD 8.86 billion by 2033, with a CAGR of 11.40% from 2025 to 2033. A more optimistic projection values the global cell cryopreservation market at USD 11.19 billion in 2024, expected to reach USD 50.88 billion by 2032, growing at a robust CAGR of 21.0%. North America held the largest share of 40.46% of the global market in 2024.

  • Cryopreservation Services Market (Global): This market was estimated to be worth USD 8 billion in 2023 and is expected to increase to USD 34.07 billion by 2030, with a projected CAGR of 23% from 2024 to 2030.

  • Cryopreservation Systems Market (Global): This market, which includes cryogenic vessels and freezers, is estimated at USD 3.9 billion in 2025 and is projected to reach USD 7.1 billion by 2035, growing at a CAGR of 6.2% over the forecast period. The USA market specifically is estimated at USD 1.4 billion in 2025 and is anticipated to reach USD 2.3 billion by 2035.

AI Analysis | Feedback

CryoPort (NASDAQ: CYRX) is positioned for future revenue growth over the next 2-3 years, driven by several key factors:

  1. Growth in Commercial Cell and Gene Therapy (CGT) Support: CryoPort has demonstrated robust double-digit revenue growth from its commercial cell and gene therapy support services, with a 29% increase year-over-year in 2025. This segment is expected to continue expanding as more advanced therapies gain market acceptance.
  2. Conversion of Clinical Trials to Commercial Therapies: The company supports a significant number of clinical trials globally, including 86 in Phase 3 and 361 in Phase 2 as of December 31, 2025. This extensive pipeline represents a substantial foundation for future commercial cell and gene therapy revenue streams as these trials progress toward regulatory approval and commercialization.
  3. Expansion of Global Footprint and Network: CryoPort is strategically expanding its global supply chain network by adding regional depots and biorepositories, including new facilities in Paris, France, and Santa Ana, California. Additionally, strategic partnerships, such as the collaboration with DHL Group, are expected to enhance CryoPort's reach and service capabilities in global growth markets like EMEA and APAC.
  4. Launch of New Products and Services: The continuous introduction of new products and service enhancements contributes to revenue growth. Recent innovations include the Cryoport Express® Cryogenic HV3 Shipping System, designed to improve patient accessibility and shipping efficiency, and other new offerings like the Fusion® 800 Series cryogenic freezer and IntegriCell™ cryopreservation services.
  5. Growth in BioStorage and BioServices: The BioStorage and BioServices segment has shown strong momentum, with revenue growing 22% annually in 2025. This area is a key component of the Life Sciences Services business and is anticipated to continue its upward trajectory as demand for specialized biological specimen storage and maintenance increases.

AI Analysis | Feedback

Here is a summary of Cryoport's capital allocation decisions over the last 3-5 years:

Share Repurchases

  • Cryoport initiated a buyback program on August 1, 2024, authorizing the repurchase of up to $200 million of its common stock and/or convertible senior notes through the end of 2027.
  • Under this program, the company agreed to repurchase approximately $160 million in aggregate principal amount of its 0.75% Convertible Senior Notes due in 2026 for an aggregate repurchase price of $141.6 million, plus accrued interest, at an 11.5% discount.
  • As of December 2, 2025, Cryoport had approximately $65.9 million remaining under its share repurchase authorization.

Outbound Investments

  • In 2025, Cryoport divested its CRYOPDP specialty courier business to DHL Group. This divestiture resulted in a net income of $112.3 million from discontinued operations for the fiscal year 2025.

Capital Expenditures

  • Cryoport's capital expenditures were $24 million in 2022, $44 million in 2023, and $20 million in 2024.
  • The company's capital spending on property, plant, and equipment was $3.45 million in Q4 2025.
  • In 2025, Cryoport increased investments into Cryoport Systems to support cell and gene therapy clients. These investments include the launch of a Global Supply Chain Center in Paris, France, the expansion of its Belgian operations, and the consolidation of three facilities in Irvine, California, into one expansive Global Supply Chain Center in Santa Ana, California.

Better Bets vs. CryoPort (CYRX)

Peer Outperformance in Air Freight & Logistics

CYRX has trailed 64% of its 11 Air Freight & Logistics peers over 5Y. Among the peers that beat it are FDX and EXPD. Air Freight & Logistics ranks 21st of 23 industries in Industrials by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Air Freight & Logistics constituents that CYRX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
100%
of 16 industry peers · 140.4% return
3Y
67%
of 12 industry peers · 48.1% return
5Y
36%
of 11 industry peers · -72.4% return
Air Freight & Logistics peers with revenue growth within 4pp of CYRX's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
CYRX CryoPort 5.6% -24.7x 140.4%48.1%-72.4% —
FDX FedEx 2.5% 19.3x 53.6%64.9%79.5% +152pp
EXPD Expeditors International of Washington 8.7% 23.6x 36.4%64.4%56.9% +129pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Industrials sector, ranked by 5Y. Air Freight & Logistics is CYRX's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Construction & Engineering 28 -11.3%82.8%103.5% FIX 1032% · STRL 856% · AGX 671%
Construction Machinery & Heavy Transportation Equipment 14 12.9%60.3%103.2% ALSN 271% · WAB 216% · CAT 201%
Marine Transportation 5 18.5%24.6%96.8% MATX 143% · KEX 125%
Aerospace & Defense 57 3.5%45.4%45.4% ATI 1006% · FTAI 838% · HWM 616%
Trading Companies & Distributors 19 18.2%31.5%38.1% DXPE 361% · URI 200% · AIT 185%
Industrial Machinery & Supplies & Components 71 5.3%42.0%31.2% CRS 812% · MLI 279% · SYM 238%
Rail Transportation 7 36.5%62.8%30.3% CSX 52% · UNP 40% · NSC 30%
Diversified Support Services 35 17.1%30.1%25.8% CXW 183% · OPLN 128% · CACI 123%
Building Products 34 1.6%1.6%15.5% MOD 1155% · GFF 408% · TT 125%
Cargo Ground Transportation 16 41.7%12.6%8.6% XPO 303% · R 281% · ARCB 27%
Office Services & Supplies 10 25.2%15.4%6.4% PBI 147% · HNI 40% · MSA 23%
Industrial Conglomerates 17 17.2%4.5%-5.0% CSW 104% · CSL 74% · DD 73%
Electrical Components & Equipment 40 -13.4%50.3%-9.4% POWL 1707% · VRT 635% · BE 473%
Data Processing & Outsourced Services 6 -8.9%-4.9%-11.0% EXLS 56% · BR 17% · G -11%
Research & Consulting Services 13 1.7%-19.2%-23.4% HURN 242% · FCN 36% · BAH 7%
Passenger Airlines 11 4.3%59.6%-30.2% LTM 3486% · UAL 127% · DAL 120%
Agricultural & Farm Machinery 17 14.8%-18.1%-32.8% DE 93% · TTC 7% · AGCO 3%
Environmental & Facilities Services 29 -19.3%15.1%-35.5% GEO 257% · CLH 164% · RSG 93%
Security & Alarm Services 9 -46.4%23.7%-39.4% BCO 85%
Human Resource & Employment Services 22 20.9%-19.8%-40.5% ADP 44% · FA 25% · PAYX 6%
Air Freight & Logistics ← 12 -31.8%-10.7%-44.0% FDX 79% · CHRW 65% · EXPD 57%
Passenger Ground Transportation 3 -18.9%26.3%-53.9% UBER 53% · CAR -54% · LYFT -64%
Airport Services 4 -43.9%-66.6%-83.5% JOBY -49%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

CYRXAZTABLFSTMORGENFDXMedian
NameCryoPort Azenta BioLife .Thermo F.Repligen FedEx  
Mkt Price20.1749.40-695.49172.65318.30172.65
Mkt Cap1.02.21.9257.39.875.16.0
Rev LTM19261410347,35180695,331710
Op Inc LTM-38-2338,863616,39232
FCF LTM-2010-27,596105-10
FCF 3Y Avg-302827,161113-28
CFO LTM1138179,324130-38
CFO 3Y Avg-462118,692142-62

Growth & Margins

CYRXAZTABLFSTMORGENFDXMedian
NameCryoPort Azenta BioLife .Thermo F.Repligen FedEx  
Rev Chg LTM11.8%4.8%25.4%8.3%13.8%7.6%10.0%
Rev Chg 3Y Avg5.6%1.0%23.0%3.0%7.5%2.5%4.3%
Rev Chg Q13.5%12.0%21.5%9.1%10.9%2.7%11.5%
QoQ Delta Rev Chg LTM3.2%2.9%5.1%2.2%2.6%0.6%2.8%
Op Inc Chg LTM2.6%15.3%118.1%10.1%1,650.9%4.4%12.7%
Op Inc Chg 3Y Avg11.5%23.1%-25.3%6.7%483.0%3.9%9.1%
Op Mgn LTM-20.0%-3.7%2.9%18.7%7.6%6.7%4.8%
Op Mgn 3Y Avg-30.0%-4.3%-8.9%18.2%3.0%6.8%-0.7%
QoQ Delta Op Mgn LTM1.2%-0.3%18.1%0.4%-0.2%-0.3%0.1%
CFO/Rev LTM5.7%6.2%16.4%19.7%16.1%-16.1%
CFO/Rev 3Y Avg-3.6%11.2%11.7%19.6%20.2%-11.7%
FCF/Rev LTM-10.3%1.6%-2.2%16.0%13.1%-1.6%
FCF/Rev 3Y Avg-21.4%5.0%1.2%16.1%16.1%-5.0%

Valuation

CYRXAZTABLFSTMORGENFDXMedian
NameCryoPort Azenta BioLife .Thermo F.Repligen FedEx  
Mkt Cap1.02.21.9257.39.875.16.0
P/S5.33.618.45.412.10.85.4
P/Op Inc-26.5-98.4632.929.0158.911.820.4
P/EBIT-30.9-98.4632.927.3318.311.519.4
P/E-24.7-18.232.536.4-827.219.30.5
P/CFO92.958.9111.827.675.2-75.2
Total Yield-4.0%-5.6%3.1%3.0%-0.1%6.6%1.5%
Dividend Yield0.0%0.0%0.0%0.3%0.0%1.4%0.0%
FCF Yield 3Y Avg-6.2%1.8%0.2%3.2%1.3%-1.3%
D/E0.20.00.00.20.10.50.1
Net D/E-0.2-0.1-0.00.1-0.00.3-0.0

Returns

CYRXAZTABLFSTMORGENFDXMedian
NameCryoPort Azenta BioLife .Thermo F.Repligen FedEx  
1M Rtn18.8%41.8%-2.4%-2.1%8.3%8.3%
3M Rtn23.7%38.7%5.9%13.4%-2.1%-2.7%9.7%
6M Rtn43.4%166.0%60.9%54.2%54.5%3.5%54.4%
12M Rtn140.4%67.9%60.7%21.2%12.8%53.6%57.2%
3Y Rtn48.1%-10.4%202.3%50.6%14.6%64.9%49.3%
1M Excs Rtn19.5%42.2%-5.0%0.4%10.4%10.4%
3M Excs Rtn23.6%38.3%7.4%13.9%-1.3%0.9%10.6%
6M Excs Rtn43.6%166.2%61.1%54.4%54.7%3.8%54.6%
12M Excs Rtn125.9%56.9%49.7%11.9%4.7%41.5%45.6%
3Y Excs Rtn11.2%-65.8%190.0%-10.6%-49.6%3.9%-3.4%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Life Sciences Services1028682138119
Life Sciences Products767289104104
Elimination of intersegment revenue-2-1-2-5 
Total176157169237223


Operating Income by Segment
$ Mil2019
Global Bioservices0
Global Logistics Solutions-18
Total-18


Assets by Segment
$ Mil2019
Global Logistics Solutions111
Global Bioservices25
Total136


Price Behavior

Price Behavior
Market Price$20.17 
Market Cap ($ Bil)1.0 
First Trading Date02/23/2007 
Distance from 52W High-2.7% 
   50 Days200 Days
DMA Price$17.70$13.87
DMA Trendupup
Distance from DMA14.0%45.5%
 3M1YR
Volatility55.0%50.7%
Downside Capture205.30149.80
Upside Capture330.87230.54
Correlation (S&P 500)46.4%44.0%
CYRX Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.792.091.711.621.611.64
Up Beta0.190.69-0.510.881.271.55
Down Beta1.882.401.511.131.331.63
Up Capture376%283%300%341%358%557%
Bmk +ve Days12182862130427
Stock +ve Days11233465131358
Down Capture290%161%180%128%129%111%
Bmk -ve Days10253664121325
Stock -ve Days11202960115385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CYRX
CYRX137.8%50.7%1.86-
Sector ETF (XLI)10.7%18.3%0.4025.2%
Equity (SPY)10.9%13.8%0.4943.5%
Gold (GLD)-8.2%29.0%-0.3013.5%
Commodities (DBC)28.8%21.5%1.07-17.4%
Real Estate (VNQ)11.2%14.2%0.5012.6%
Bitcoin (BTCUSD)-29.6%43.7%-0.6930.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CYRX
CYRX-23.2%77.9%-0.01-
Sector ETF (XLI)10.8%17.8%0.4437.4%
Equity (SPY)11.0%17.3%0.4642.2%
Gold (GLD)14.5%19.2%0.606.5%
Commodities (DBC)6.8%19.6%0.243.7%
Real Estate (VNQ)1.1%19.0%-0.0537.2%
Bitcoin (BTCUSD)-0.0%51.4%0.1823.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CYRX
CYRX25.7%72.3%0.64-
Sector ETF (XLI)12.9%20.1%0.5627.6%
Equity (SPY)14.9%18.0%0.7034.3%
Gold (GLD)10.9%16.6%0.536.0%
Commodities (DBC)7.2%18.2%0.315.8%
Real Estate (VNQ)5.8%20.7%0.2427.0%
Bitcoin (BTCUSD)57.1%66.3%0.9713.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity3.5 Mil
Short Interest: % Change Since 1015202637.3%
Average Daily Volume0.8 Mil
Days-to-Cover Short Interest4.1 days
Basic Shares Quantity50.7 Mil
Short % of Basic Shares6.9%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/202619.0%25.2% 
8/6/20262.8%2.9%7.5%
5/4/202619.4%29.0%61.6%
3/3/20262.9%-7.2%0.2%
11/4/2025-7.5%-4.0%3.5%
8/6/2025-6.3%3.8%18.3%
5/7/202523.3%14.3%23.7%
3/4/202530.6%31.4%21.7%
...
SUMMARY STATS   
# Positive131514
# Negative121010
Median Positive10.0%9.1%10.6%
Median Negative-5.2%-8.5%-11.3%
Max Positive30.6%39.4%61.6%
Max Negative-32.0%-24.1%-32.3%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/202619.0%25.2% 
8/6/20262.8%2.9%7.5%
5/4/202619.4%29.0%61.6%
3/3/20262.9%-7.2%0.2%
11/4/2025-7.5%-4.0%3.5%
8/6/2025-6.3%3.8%18.3%
5/7/202523.3%14.3%23.7%
3/4/202530.6%31.4%21.7%
11/7/2024-3.6%-8.0%3.9%
8/6/2024-0.3%5.3%5.4%
5/7/2024-19.5%-18.0%-32.3%
3/12/2024-11.9%1.5%10.8%
11/8/202310.0%29.5%48.3%
8/9/2023-1.8%-4.6%-6.4%
5/4/202313.7%3.6%-6.0%
2/23/20238.8%9.1%10.3%
11/3/2022-32.0%-24.1%-31.3%
8/4/20226.7%18.1%-16.2%
5/5/2022-1.6%-6.9%3.5%
2/24/20224.4%1.6%-2.7%
11/4/2021-2.4%-9.6%-21.6%
8/5/2021-4.9%-8.9%-0.7%
5/4/202111.6%2.4%-0.1%
3/1/2021-5.6%-22.4%-20.7%
11/5/20205.5%39.4%16.7%
SUMMARY STATS   
# Positive131514
# Negative121010
Median Positive10.0%9.1%10.6%
Median Negative-5.2%-8.5%-11.3%
Max Positive30.6%39.4%61.6%
Max Negative-32.0%-24.1%-32.3%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/06/202610-Q
03/31/202605/05/202610-Q
12/31/202503/05/202610-K
09/30/202511/06/202510-Q
06/30/202508/12/202510-Q
03/31/202505/08/202510-Q
12/31/202403/07/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/08/202410-Q
12/31/202303/13/202410-K
09/30/202311/09/202310-Q
06/30/202308/09/202310-Q
03/31/202305/04/202310-Q
12/31/202202/28/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/06/202610-Q
03/31/202605/05/202610-Q
12/31/202503/05/202610-K
09/30/202511/06/202510-Q
06/30/202508/12/202510-Q
03/31/202505/08/202510-Q
12/31/202403/07/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/08/202410-Q
12/31/202303/13/202410-K
09/30/202311/09/202310-Q
06/30/202308/09/202310-Q
03/31/202305/04/202310-Q
12/31/202202/28/202310-K
09/30/202211/04/202210-Q
06/30/202208/04/202210-Q
03/31/202205/05/202210-Q
12/31/202102/28/202210-K
09/30/202111/04/202110-Q
06/30/202108/06/202110-Q
03/31/202105/06/202110-Q
12/31/202003/01/202110-K
09/30/202011/06/202010-Q
06/30/202008/10/202010-Q
03/31/202005/08/202010-Q
12/31/201903/10/202010-K

Recent Forward Guidance

Updated 11/6/2026

Latest: Q3 2026 Earnings Reported 11/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q4 2026 Anticipated Customer New Therapy ApprovalsReported 2    
2026 Anticipated Customer BLA or MAA FilingsReported 5 -54.5% LoweredGuidance: 11 for 2026
2026 RevenueReported197.00 Mil198.00 Mil199.00 Mil   


Prior: Q2 2026 Earnings Reported 8/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 BLA/MAA applicationsReported 11    
2026 New therapy approvalsReported 5    
2026 Label/geographic expansion approvalsReported 1    

Q1 2026 Earnings Reported 5/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported192.00 Mil194.00 Mil196.00 Mil  RaisedGuidance: 192.00 Mil for 2026

Q4 2025 Earnings Reported 3/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported190.00 Mil192.00 Mil194.00 Mil11.6% Higher NewGuidance: 172.00 Mil for 2025

Insider Activity

Updated 11/12/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Sawicki, Mark WChief Scientific OfficerDirectSell1112202619.9310,000199,2611,840,295Form
2Hancock, Daniel MDirectSell1112202620.2174,3791,502,9761,395,334Form
3Shelton, JerrellPresident, CEODirectSell811202614.9128,800429,38517,918,085Form
4Zecchini, Edward JChief Digital and Tech OfficerDirectSell612202614.4733,600486,2391,587,788Form
5Zecchini, Edward JChief Digital and Tech OfficerDirectSell612202615.231,40021,3241,671,174Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Sawicki, Mark WChief Scientific OfficerDirectSell1112202619.9310,000199,2611,840,295Form
2Hancock, Daniel MDirectSell1112202620.2174,3791,502,9761,395,334Form
3Shelton, JerrellPresident, CEODirectSell811202614.9128,800429,38517,918,085Form
4Zecchini, Edward JChief Digital and Tech OfficerDirectSell612202614.4733,600486,2391,587,788Form
5Zecchini, Edward JChief Digital and Tech OfficerDirectSell612202615.231,40021,3241,671,174Form
6Mandalam, RamkumarDirectSell608202615.4423,214358,4521,048,365Form
7Stefanovich, RobertChief Financial OfficerDirectSell608202616.27169,4272,756,9841,787,523Form
8Stefanovich, RobertChief Financial OfficerDirectSell32520268.181,0948,9492,284,486Form
9Shelton, JerrellPresident, CEODirectSell32520268.182,89423,6738,602,145Form
10Sawicki, Mark WChief Scientific OfficerDirectSell32520268.181,34110,969837,272Form
11Zecchini, Edward JSee RemarksDirectSell31720268.002,01416,112877,752Form
12Shelton, JerrellPresident, CEODirectSell31720268.007,91863,3448,436,008Form
13Sawicki, Mark WChief Scientific OfficerDirectSell31720268.003,23525,880829,576Form
14Stefanovich, RobertChief Financial OfficerDirectSell31620268.002,74321,9442,242,968Form
15Stefanovich, RobertChief Financial OfficerDirectSell31620267.7638,700300,3861,984,726Form
16Mandalam, RamkumarDirectSell121220259.9911,570115,540806,466Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Cadian Capital Management, LP$39.5 Mil4.8%23Hold13F
Mak Capital One LLC$11.8 Mil2.0%21ADD +18.7%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Mak Capital One LLC$11.8 Mil2.0%21ADD +18.7%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Cadian Capital Management, LP$39.5 Mil4.8%23Hold13F
Mak Capital One LLC$11.8 Mil2.0%21ADD +18.7%13F
Core Cache Last Updated: 11/18/2026